Summit Therapeutics (SMMT) net assets (shareholders' equity)

Net assets · fiscal 2025
$658.86M

Summit Therapeutics (SMMT) had net assets of $658.86M at the end of fiscal 2025 (December 31, 2025). That is 69.5% higher than the $388.75M of fiscal 2024. Figures as of 19 Nov 2026, 01:20 UTC, from the company's filings with the SEC and Yahoo Finance.

Key facts

Net assets, fiscal 2025
$658.86M
Change on fiscal 2024
+69.5%
Growth, 5 years
+52.7% a year
Highest on record
$658.86Mfiscal 2025
Lowest on record
$57.59Mfiscal 2019
Fiscal years on record
72019–2025

Figures as of . Older fiscal years come from the company's filings with the SEC, recent ones from Yahoo Finance. Amounts are in USD. Figures, not advice.

Summit Therapeutics net assets (shareholders' equity), in more detail

Over the five fiscal years to 2025 net assets grew at a compound 52.7% a year. Across the 7 fiscal years on record (2019–2025), the highest was $658.86M in fiscal 2025 and the lowest $57.59M in fiscal 2019.

History · 7 fiscal years

Net assets by fiscal year

Summit Therapeutics net assets (shareholders' equity), year by year

Summit Therapeutics (SMMT) net assets (shareholders' equity) by fiscal year
Fiscal yearNet assetsChangeYear ended
2025$658.86M 69.5% up
2024$388.75M 400.4% up
2023$77.69M 38.7% down
2022$126.65M 52.1% up
2021$83.28M 4.8% up
2020$79.45M 38.0% up
2019$57.59M—

Change is on the fiscal year before; a dash means that year is not on record or the earlier figure was not positive. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.

Method

How it is calculated

Net assets is shareholders' equity on the balance sheet at the fiscal year-end: total assets minus total liabilities, also called book value.

How to read it

Large buybacks and write-offs shrink it without the business getting worse, so a falling or negative figure needs the reason before a verdict.

Net assets at health care companies of similar size

Net assets of Summit Therapeutics and comparable companies
CompanyNet assetsFiscal year
BridgeBio Pharma BBIO-$2.09B2025
Summit Therapeutics SMMT$658.86M2025
Glaukos GKOS$656.16M2025
Encompass Health EHC$2.44B2025
BrightSpring Health Services BTSG$1.88B2025
Baxter International BAX$6.13B2025

The latest fiscal year on record for each company, in the currency it reports in. Fiscal years end at different times of year.

More on SMMT

Summit Therapeutics, figure by figure

Summit Therapeutics (SMMT) overview: price, valuation and scorecardAll health care companies by market value

Summit Therapeutics net assets (shareholders' equity): questions and answers

What are Summit Therapeutics's net assets?

Summit Therapeutics (SMMT) had net assets of $658.86M at the end of fiscal 2025 (December 31, 2025). That is 69.5% higher than the $388.75M of fiscal 2024.

What is the growth rate of Summit Therapeutics's net assets?

Over the five fiscal years to 2025 net assets grew at a compound 52.7% a year.

What are the highest and lowest net assets figures on record for Summit Therapeutics?

Across the 7 fiscal years on record (2019–2025), the highest was $658.86M in fiscal 2025 and the lowest $57.59M in fiscal 2019.

How is Summit Therapeutics's net assets calculated?

Net assets is shareholders' equity on the balance sheet at the fiscal year-end: total assets minus total liabilities, also called book value. For Summit Therapeutics it is on record here for 7 fiscal years, 2019 to 2025.

Fiscal years are named for the calendar year they end in.

Cite this page

Funkfolio, “Summit Therapeutics (SMMT) net assets (shareholders' equity)”, data as of 19 November 2026. https://funkfolio.com/stock/SMMT/net-assets

Underlying data: the company's filings with the SEC and Yahoo Finance.